2010
DOI: 10.1038/bmt.2010.207
|View full text |Cite
|
Sign up to set email alerts
|

Role of autotransplantation in the treatment of acute promyelocytic leukemia patients in remission: Fukuoka BMT Group observations and a literature review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
9
0

Year Published

2011
2011
2020
2020

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 13 publications
(9 citation statements)
references
References 27 publications
0
9
0
Order By: Relevance
“…29 Results of 1 prospective study in 15 patients with APL suggest using PCR status to help determine auto- vs. allo-HCT, which concluded that, for patients with APL in CR2 and PCR negativity, auto-HCT be considered and that, for patients with PCR positivity, more aggressive regimens be considered, including those regimens based on allo-HCT. 27 In our study, 7 (100%) of 7 patients who underwent auto-HCT only as HCT-based therapy were in CR at the time of HCT, and, of these patients, 5 (71%) of 7 were found to be in MR. All but one of these patients was in CR2 or beyond. The 7-year relapse-free survival for the auto-HCT group was 68.6% and the 7-year OS was 85.7%, with a TRM of 10%, which suggests that auto-HCT is indeed an effective treatment in CR2 and beyond for patients with relapsed APL.…”
Section: Discussionmentioning
confidence: 47%
See 1 more Smart Citation
“…29 Results of 1 prospective study in 15 patients with APL suggest using PCR status to help determine auto- vs. allo-HCT, which concluded that, for patients with APL in CR2 and PCR negativity, auto-HCT be considered and that, for patients with PCR positivity, more aggressive regimens be considered, including those regimens based on allo-HCT. 27 In our study, 7 (100%) of 7 patients who underwent auto-HCT only as HCT-based therapy were in CR at the time of HCT, and, of these patients, 5 (71%) of 7 were found to be in MR. All but one of these patients was in CR2 or beyond. The 7-year relapse-free survival for the auto-HCT group was 68.6% and the 7-year OS was 85.7%, with a TRM of 10%, which suggests that auto-HCT is indeed an effective treatment in CR2 and beyond for patients with relapsed APL.…”
Section: Discussionmentioning
confidence: 47%
“…18 A retrospective study of 26 patients with APL who achieved either CR1 or CR2 and who underwent auto-HCT demonstrated that this might be an effective treatment option, especially in high-risk patients with APL. 27 In another study, of 37 patients with relapsed APL, 14 patients received auto-HCT. Compared with the 19 patients who received CT alone, the investigators concluded that treatment that involved an auto-HCT resulted in significantly superior results after a remission induction with ATO-based regimens at relapse.…”
Section: Discussionmentioning
confidence: 99%
“…Recently, the Auto-PBSCT on tumor has got an extensive application in tumor treatment. It's safer and more effective than allograft because of less rejection, material easier to get and rapid bone marrow hematopoietic recovery (Palmieri et al, 2007;Uehara et al, 2008;Niwa et al, 2009;Kamimura et al, 2011). In this study, 3 patients received Auto-PBSCT treatment and 2 achieved complete remission.…”
Section: Discussionmentioning
confidence: 99%
“…75 For the 15% patients who relapse, ASCT with PML-RAR-negative cells is a therapeutic option in CR2. [76][77][78] In the largest case series reported recently, CIBMTR 79 reviewed 294 patients with M3 AML treated with allo-HSCT (n = 232) or ASCT (n = 62). Multivariate analysis showed that, compared with allo-HSCT, ASCT was associated with higher LFS (63% vs 50%, P = 0.01) and OS (75% vs 54%, P = 0.0006) at 5 years.…”
mentioning
confidence: 99%